Search Results
Cotargeting oncogenic protein translation and apoptosis in acute myeloid leukemia
The focus of my research is to evaluate the efficacy of and to unravel the molecular mechanisms underpinning a novel drug combination in AML targeting oncogenic protein translation and apoptosis. We will utilize genetic perturbation and other orthogonal approaches, including in vitro and ex vivo assays, and in vivo AML PDX models. The goal of my research is to transform the clinical management of AML patients, particularly for relapsed and difficult-to-treat subgroups.T cells with native and chimeric receptors against multiple tumor targets for acute myeloid leukemia
Adoptive T cell therapies for acute myeloid leukemia face numerous hurdles such as limited target antigens, immunosuppressive tumor environment as well as the loss of efficacy due to downregulation of the targeted antigen. The goal of our project is to address some of these challenges with a single T cell product targeting multiple tumor associated antigens that have limited expression on healthy tissues via a novel combination of native T cell receptor and gene engineered CAR targeting.Leveraging Susceptible Populations and Unique Resources in a Pathway to Prevention of Childhood Acute Lymphoblastic Leukemia
The focus of my research is to understand the causes and early-life origins of acute lymphoblastic leukemia (ALL). We use a two-pronged approach: 1) conducting epidemiological studies of ALL in susceptible populations to understand genetic predisposition, and 2) investigating the in utero origins of ALL across subtypes. Our goals are to identify children at the highest risk of developing ALL through genetic screening and to lay the groundwork for precision prevention strategies.Companies Take on Blood Cancer
Corporations usually have enough on their plate, just taking care of business, but at least one has found a creative way to also help generate millions of dollars to fund blood cancer research, education and patient services.
Therapeutic targeting of T-cell acute lymphoblastic leukemia using an AKR1C3-activated prodrug
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that is exceptionally difficult to cure after relapse. We have previously shown that T-ALL expresses high levels of the enzyme AKR1C3, leading to clinical trials of AKR1C3-activated prodrugs. This project will focus on identifying the determinants of responses to AKR1C3-activated prodrugs in T-ALL and optimizing the use of a second generation AKR1C3-activated prodrug, SN36008, in T-ALL patient-derived xenografts.Researcher Q&A: Christopher Cogle, M.D., University of Florida
Christopher Cogle, M.D., Professor of Medicine, University of Florida, Pierre Chagnon Professor of Stem Cell Biology and Bone Marrow Transplant, is the recipient of an LLS Scholar in Clinical Research grant through our Career Development Program. He also has a project supported through LLS’s Therapy Acceleration Program. Dr. Cogle explains his work advancing an investigational approach to treating patients with acute myeloid leukemia and myelodysplastic syndromes.
Can We Start Using The Word “Cure?” #ASH17
Today at the #ASH17 (American Society of Hematology) conference in Atlanta, researchers presented the latest compelling data from thousands of clinical trials, revealing how experimental therapies, or approved therapies being tested in new ways, have worked in treating blood cancer patients. Among the presentations were several hundred projects across a spectrum of diseases that benefited in some way from support from The Leukemia & Lymphoma Society (LLS).
Putting Patients at the Center of Care at #ASCO16
The American Society of Clinical Oncology (#ASCO16) annual meeting kicked off today as more than 30,000 researchers from around the world converged in Chicago to share their latest clinical findings on treatments and diagnostics for all cancers, and to exchange ideas about how to improve outcomes for cancer patients.
“I Don’t Have Money but I Have Time”
Three or four days a week for the past five years, Dorothy Spriggs has been showing up for work at The Leukemia & Lymphoma Society’s (LLS) Maryland chapter. However, instead of a paycheck, she is earning the satisfaction of knowing she is doing her part to give back and helping others with blood cancer.
At age 73, the Baltimore woman known as “Ms. Dotti” has no plans to stop. She’s enjoying it way too much.
“It’s the joy of being able to give back in a small way,” she said. “When I look at what the staff do, it amazes me. What I do is kind of small compared to them.”
Progress and Challenges in Treating the Blood Cancers: #ASH19
It’s that time of year again, when more than 30,000 scientists specializing in blood cancers and other blood disorders, oncologists and hematologists, pharmaceutical and biotechnology company representatives, and cancer patient advocacy organizations gather in one place to learn about the latest progress in treatments and share new ideas.
This year, we’re in sunny Orlando for the 61st ASH (American Society of Hematology) Annual meeting and Exposition.
6-Thioguanine
6-Thioguanine is FDA approved for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
Cleaning Tips to Help Keep You and Your Loved Ones Safe
The Leukemia & Lymphoma Society (LLS) is here to help. We’ve put together guidance from the U.S. Centers for Disease Control and Prevention (CDC) and other tips to help caregivers and families keep their homes clean and healthy.
Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma
Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.What I’ve Learned: Tips for Parents of Kids with ALL
My daughter Mackenzie was diagnosed with acute lymphoblastic leukemia (ALL) in January 2014. Despite being the most common form of childhood cancer that has a very prescribed protocol with better-than-most survival rates, the diagnosis petrified me. My nine-year-old had cancer.
CAR-T Pioneer Dr. Carl June Elected to the U.S. National Academy of Science
The Leukemia & Lymphoma Society (LLS) congratulates Carl June, MD, of the University of Pennsylvania, whose groundbreaking research ushered in a new era in cancer immunotherapy, for his election into the U.S. National Academy of Science (U.S. NAS). Dr. June earned this prestigious honor through recognition by his peers for his “distinguished and continuing achievements in original research.”
SAVE THE DATE AGAIN: GETTING MARRIED AFTER CANCER
My name’s Dustin. December 3, 2016 was the date that I was supposed to get married to KT. It was a Saturday. We had that date set for over a year, but there was no wedding—we canceled it the Tuesday before. KT informed most of our guests with an explanatory text: “So, I have some unfortunate news. We’re going to have to call off the wedding this weekend. Dust got cold feet…and leukemia.”
Shop Online and In-Store at Walgreens to Support LLS
The Leukemia & Lymphoma Society (LLS) and Walgreens are in your corner.
Since 2019, Walgreens has helped to raise more than $30 million for LLS and Susan G. Komen, all with a clear goal in mind: to advance research for tough-to-treat cancers and increase equitable access to care.
Volunteers: The Engine Powering LLS’s Mission
I was always aware that volunteers with The Leukemia & Lymphoma Society (LLS) drive impact for blood cancer patients and families. But it wasn’t until Thanksgiving Day 2007 that I discovered the full force of their power. My wife, Holly, had recently been diagnosed with follicular lymphoma and our family was still reeling from the news. She was feeling quite ill, and we were exhausted with worry and trying to keep life as normal as possible for our two young children.
Moms In Training: Keeping on Track
Staying on track while you train for a walk or run event can be challenging at times. This is especially true for busy moms who barely have enough time to work out, let alone track their fitness progress.
Coming Soon: A Brave New World
Research is inching us closer to cures for blood cancer every day – among them, therapies that unleash the immune system, reprogramming of T-cells to track down cancer cells, and personalized treatments based on a patient’s genetic make-up.